StreetInsider.com News Articles

Jasper Therapeutics explores strategic alternatives including potential sale

Mon, 01 Jun 2026 08:01:52 -0400

Jasper Therapeutics Inc. (NASDAQ: JSPR) announced that its board of directors has initiated a review of strategic alternatives aimed at maximizing shareholder value. The clinical-stage biotechnology company said it is evaluating options including asset sales, licensing agreements, collaborations, a company sale, business combination, merger or an orderly wind-down of operations.

The Redwood City, California-based company develops briquilimab, an antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria and asthma. Jasper said it will continue evaluating cost-saving measures to preserve cash while maintaining regulatory and financial reporting compliance during the strategic review.

The company

Jasper Therapeutics explores strategic alternatives including potential sale

Mon, 01 Jun 2026 08:01:52 -0400

The company

Jasper Therapeutics explores strategic alternatives including potential sale

Mon, 01 Jun 2026 08:01:52 -0400

The company

Form 8-K Jasper Therapeutics, For: Jun 01

Mon, 01 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260601/26579593.html

Form 8-K Jasper Therapeutics, For: Jun 01

Mon, 01 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260601/26579593.html

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Mon, 01 Jun 2026 08:00:00 -0400

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives being evaluated include, among other options, a sale of assets, licensing of assets, collaborations, a sale

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Mon, 01 Jun 2026 08:00:00 -0400

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Mon, 01 Jun 2026 08:00:00 -0400

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Mon, 01 Jun 2026 08:00:00 -0400

Form 8-K Jasper Therapeutics, For: May 15

Thu, 21 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260521/26535037.html

Form 8-K Jasper Therapeutics, For: May 15

Thu, 21 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260521/26535037.html

Jasper Therapeutics (JSPR) Reiterated at Market Outperform by Citizens After Q1 Results

Mon, 18 May 2026 07:24:42 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $6.00 price target on Jasper Therapeutics (NASDAQ: JSPR).

The analyst commented, "Jeet Mahal was brought in as CEO to secure funding for the Phase 2b and beyond, and we believe a fresh voice and the finalized Ph2b regimen could be useful for JSPR. The data demonstrate that briquilimab is a useful therapy in CSU, and we believe it is differentiated. The primary question that remains is financing of the Ph2b development — management believes it has the necessary data to make headway and the overall regulatory pathway in CSU has been

Jasper Therapeutics (JSPR) PT Lowered to $3 at RBC Capital

Fri, 15 May 2026 07:33:44 -0400

RBC Capital analyst Leonid Timashev lowered the price target on Jasper Therapeutics (NASDAQ: JSPR) to $3.00 (from $4.00) while maintaining a Sector Perform rating.

TD Cowen Downgrades Jasper Therapeutics (JSPR) to Hold, 'now at a critical juncture'

Fri, 15 May 2026 05:30:16 -0400

(Updated - May 15, 2026 5:30 AM EDT)

TD Cowen analyst Yaron Werber downgraded Jasper Therapeutics (NASDAQ: JSPR) from Buy to Hold.

The analyst comments "Our Take: Jasper At A Crossroads – While There Is An Opportunity To Succeed, Multiple Layers Of Uncertainty Lead Us To Move To The Sidelines. Jasper is now at a critical juncture. The good news is that in the past month, they have refiled an updated protocol with the FDA for their planned Ph2b CSU study, which outlines a sensible Ph2b plan with two doses that could address some of the pitfalls of their prior data wherein

TD Cowen Downgrades Jasper Therapeutics (JSPR) to Hold, 'now at a critical juncture'

Fri, 15 May 2026 05:30:16 -0400

(Updated - May 15, 2026 5:30 AM EDT)

TD Cowen analyst Yaron Werber downgraded Jasper Therapeutics (NASDAQ: JSPR) from Buy to Hold.

TD Cowen Downgrades Jasper Therapeutics (JSPR) to Hold, 'now at a critical juncture'

Fri, 15 May 2026 05:30:16 -0400

(Updated - May 15, 2026 5:30 AM EDT)

TD Cowen analyst Yaron Werber downgraded Jasper Therapeutics (NASDAQ: JSPR) from Buy to Hold.

TD Cowen Downgrades Jasper Therapeutics (JSPR) to Hold, 'now at a critical juncture'

Fri, 15 May 2026 05:30:16 -0400

(Updated - May 15, 2026 5:30 AM EDT)

TD Cowen analyst Yaron Werber downgraded Jasper Therapeutics (NASDAQ: JSPR) from Buy to Hold.

Jasper Therapeutics (JSPR) Misses Q1 EPS by 4c

Thu, 14 May 2026 17:46:20 -0400

Jasper Therapeutics (NASDAQ: JSPR) reported Q1 EPS of ($0.04).

For earnings history and earnings-related data on Jasper Therapeutics (JSPR) click here.

Form 10-Q Jasper Therapeutics, For: Mar 31

Thu, 14 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260514/26494699.html

Form 10-Q Jasper Therapeutics, For: Mar 31

Thu, 14 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260514/26494699.html

Form 8-K Jasper Therapeutics, For: May 14

Thu, 14 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260514/26494670.html

Form 8-K Jasper Therapeutics, For: May 14

Thu, 14 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260514/26494670.html

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 14 May 2026 16:05:00 -0400

REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update.

"In recent months, we have continued to advance the briquilimab development program in CSU," said Jeet Mahal, President and Chief Executive Officer of Jasper. “Following our positive clinical data

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 14 May 2026 16:05:00 -0400

"In recent months, we have continued to advance the briquilimab development program in CSU," said Jeet Mahal, President and Chief Executive Officer of Jasper. “Following our positive clinical data

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 14 May 2026 16:05:00 -0400

"In recent months, we have continued to advance the briquilimab development program in CSU," said Jeet Mahal, President and Chief Executive Officer of Jasper. “Following our positive clinical data